Skip to main content
ARS Home » Midwest Area » Ames, Iowa » National Animal Disease Center » Infectious Bacterial Diseases Research » Research » Publications at this Location » Publication #189226

Title: An ESAT-6:CFP10 DNA vaccine Administered in Conjunction with Mycobacterium bovis BCG confers Protection to Cattle Challenged with Virulent M. bovis

item Maue, Alexander
item Waters, Wade
item Palmer, Mitchell
item Nonnecke, Brian
item Minion, F
item Brown, Wendy
item Norimine, Junzo
item Foote, Monica
item Scherer, Charles
item Estes, D

Submitted to: Vaccine
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: 3/30/2007
Publication Date: 4/24/2007
Citation: Maue, A.C., Waters, W.R., Palmer, M.V., Nonnecke, B.J., Minion, F.C., Brown, W.C., Norimine, J., Foote, M., Scherer, C.F., Estes, D.M. 2007. An ESAT-6:CFP10 DNA vaccine Administered in Conjunction with Mycobacterium bovis BCG confers Protection to Cattle Challenged with Virulent M. bovis. Vaccine. 25(24):4735-4746.

Interpretive Summary: Despite highly successful eradication efforts in several countries, tuberculosis of cattle remains a serious health concern worldwide. In addition, a recent outbreak of tuberculosis in white-tailed deer in Michigan has seriously hindered eradication efforts within the United States. Improved strategies to prevent tuberculosis infection in cattle and wildlife species are needed. In the present study, a novel experimental tuberculosis vaccine was evaluated for activity in the induction of an immune response. The immune response was enhanced when a host stimulatory factor was included with the vaccine. These findings indicate that new and improved vaccines may prove superior to traditional TB vaccines.

Technical Abstract: The potency of genetic immunization observed in the mouse has demonstrated the utility of DNA vaccines to induce cell-mediated and humoral immune responses. However, it has been relatively difficult to generate comparable responses in non-rodent species. The use of molecular adjuvants may increase the magnitude of these suboptimal responses. In this study, we demonstrate that the co-administration of plasmid-encoded GM-CSF and CD80/CD86 with a novel ESAT-6:CFP10 DNA vaccine against bovine tuberculosis enhances antigen-specific cell-mediated immune responses. ESAT-6:CFP10 + GM-CSF + CD80/CD86 DNA vaccinated animals exhibited significant (p < 0.01) antigen-specific proliferative responses compared to other DNA vaccinates. Increased expression (p < 0.05) of CD25 on PBMC from ESAT-6:CFP10 + GM-CSF + CD80/CD86 DNA vaccinates was associated with increased proliferation, as compared to control DNA vaccinates. Significant (p < 0.05) numbers of ESAT-6:CFP10-specific IFN-gamma producing cells were evident from all ESAT-6:CFP10 DNA vaccinated animals compared to control DNA vaccinates. However, the greatest increase in IFN-gamma producing cells was from animals vaccinated with ESAT-6:CFP10 + GM-CSF + CD80/CD86 DNA. In a aerosol challenge trial, calves vaccinated as neonates with Mycobacterium bovis BCG and ESAT-6:CFP10 + GM-CSF + CD80/CD86 DNA exhibited decreased lesion severity in the lung and lung-associated lymph nodes following viruluent M. bovis challenge compared to other vaccinated animals or non-vaccinated controls. These data suggest that a combined vaccine regimen of M. bovis BCG and a candidate ESAT-6:CFP10 DNA vaccine may offer greater protection against tuberculosis in cattle than vaccination with BCG alone.